PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 ビュー
• 07/08/23
0
0
埋め込む
administrator
加入者
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
もっと見せる
フェイスブックのコメント
SORT BY-
トップコメント
-
最新のコメント